Blood test 'could predict whether women with breast cancer will respond to treatment'

The blood test could help predict whether women will respond to treatment
Rui Vieira/PA
Megan White2 June 2019

A new blood test could predict the effectiveness of breast cancer drugs and whether or not the disease is likely to return, scientists have said.

Scientists said the "liquid biopsy" can detect genetic changes in the tumours of patients and indicate if they are less likely to respond to a new targeted drug.

The research, from the Institute of Cancer Research in London, was presented at the annual meeting of the American Society of Clinical Oncology in Chicago.

Professor Paul Workman, chief executive of the Institute of Cancer Research, said: "Cancer's ability to evolve to become resistant to treatment is the greatest challenge we face in improving patients' survival and quality of life.

File photo: A monitor shows the image of a breast cancer
REUTERS

"So-called liquid biopsy tests like this one are a key part of our toolkit in staying on top of cancers' adaptability and evolution, and picking up the earliest signs of drug resistance.

"Detecting the potential of cancers to evolve resistance could allow us to predict cancer's next move and to respond with adaptable new treatment plans."

Fragments of cancer DNA in the blood samples of 310 women with oestrogen receptor positive breast cancer - the most common form of the disease - were analysed during the study.

The patients had advanced breast cancer and were taking part in a trial of targeted drug palbociclib and hormone therapy fulvestrant.

The research team found 42 per cent of the women had one or more of three changes in the tumour DNA in their bloodstream that put them at risk of early relapse.

Women whose circulating tumour DNA contained changes in the cancer gene p53 saw their cancer return after an average of 3.7 months.

This compared to 12.7 months among women without the gene changes. An increase in other genes was also found to predict when the cancer might return.

Professor Nicholas Turner, from the Institute of Cancer Research and Royal Marsden, said: "Exciting new targeted treatments like palbociclib are beginning to have a real impact on survival for women with breast cancer, but unfortunately many tumours which initially respond will later develop resistance and come back.

"Our study found that a new genetic test could detect right at the start of treatment those women whose cancers were most likely to develop resistance quickly to palbociclib.

"We could then adjust their treatment plan accordingly - trialling additional treatments from the outset to try and prevent resistance, or planning for a switch to another treatment as soon as resistance develops.

"We now need to assess in a clinical trial whether helping direct women's care with this new test can offer improved survival and quality of life."

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in

MORE ABOUT